This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Bipotrol, Carbamazepine Extended Release, SPD417, ERC-CBZ
Description: Equetro is a twice daily formulation of carbamazepine. The mechanisms of action of carbamazepine in the treatment of bipolar disorder has not been elucidated. Although numerous pharmacological effects of carbamazepine have been described (e.g., modulation of ion channels [sodium and calcium], receptor-mediated neurotransmission[GABAergic, glutamatergic, and monoaminergic], and intracellular signaling pathways), the contribution of these effects to the efficacy of carbamazepine in bipolar disorder is unknown.
Deal Structure: In September 2007, Validus Pharmaceuticals announced that it had acquired Equetro (carbamazepine) extended release capsules, from Shire plc.
Pink Sheet Shire Adds Equetro To CNS Product Lineup
Additional information available to subscribers only: